Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) said on Thursday that it will receive SEK117.2m in royalties from third-quarter 2025 global sales of Leqembi (lecanemab), recorded at JPY18bn by its Japanese partner Eisai Co Ltd (TYO:4523).

This represents an increase of approximately 68% compared with the royalty paid to BioArctic for the same period in 2024.

Leqembi, developed through a strategic alliance between BioArctic and Eisai, is a monoclonal antibody targeting aggregated soluble and insoluble forms of amyloid-beta for the treatment of early Alzheimer's disease. The therapy is approved in 51 countries, including the United States, Japan, China, and the EU, and is under regulatory review in nine additional markets.

BioArctic retains commercialisation rights in the Nordic region and is preparing to launch Leqembi in collaboration with Eisai. The company does not bear development costs and is entitled to milestone payments and royalties on global sales. The full third-quarter report for BioArctic is scheduled for release on 13 November 2025.